Psychotic DisordersYEAHNCT03332966
Youth Experiences and Health Study
An observational study of Psychotic Disorders and Psychiatric Hospitalization, run by Finnish Institute for Health and Welfare at 3 sites in Finland.
Trial summary
This study aims to identify unusual experiences and psychiatric symptoms that indicate a heightened risk for severe mental disorders - especially psychoses. It is important to develop reliable questionnaire methods that are cost-effective in first-stage screening, leading to in-depth assessments and targeted care. Read more about this study
- Who is it for?
- Ages 15 to 18 years
- Conditions the study is for
- Psychotic Disorders, Psychiatric Hospitalization, Prodromal Symptoms
- What is being tested?
- Psychiatric questionnaires and Semi-structured psychiatric interview
- How many people
- 1,000 participants
- Where
- 3 sitesFinland
- Study dates
- 1 Dec 2019to 31 Dec 2024
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: All patients in the adolescent health clinics in three hospital districts of Finland.
Who may be able to join
- Start of care in adolescent mental health clinic
Who cannot join
- Previous diagnosis of psychotic disorder
Trial locations and contacts
3 sites in 1 country.
Finland3 sites, 3 recruiting
- Not yet recruiting
HUS Helsinki University Hospital, adolescent psychiatry clinics
Helsinki, 00029
Laura Häkkinen, MD, PhD, +358504412207, Laura.Hakkinen@hus.fi
Mikko Kinnunen, MD, PhD, Mikko.Kinnunen@hus.fi
- Recruiting
Northern Ostrobothnia Hospital District, Adolescent Mental Health Clinic
Oulu, 90230
Juha T Karvonen, MD, +358400254063, juha.karvonen@ppshp.fi
Mauri Koskela, +358400278721, Mauri.Koskela@ppshp.fi
- Recruiting
Pirkanmaa Hospital District, Tays Central Hospital, Adolescent psychiatry clinic
Tampere, 33521
Riittakerttu Kaltiala-Heino, MD, PhD, Riittakerttu.Kaltiala-Heino@pshp.fi
Jaana Ruuska, MD, +358505766292, jaana.ruuska@pshp.fi
About this study
Official title: Youth Experiences and Health (YEAH) Study - Psychological Symptoms and Resources As Predictors of Mental Health Among Treatment-seeking Adolescents
This study aims to identify unusual experiences and psychiatric symptoms that indicate a heightened risk for severe mental disorders - especially psychoses. It is important to develop reliable questionnaire methods that are cost-effective in first-stage screening, leading to in-depth assessments and targeted care. However, existing psychosis-risk questionnaires are limited in content, intended for adults, and have been insufficiently tested for actual predictive value. Therefore we will collect a new, large dataset from an unselected group of adolescents entering psychiatric care in three major urban areas of Finland. Comprehensive national health care registers will be used to assess how well the selected experiences and symptoms predict the participants' mental health over the following few years.
Read the detailed description
The current research will identify specific self-reported risk symptoms for psychosis and psychiatric hospitalization. Data will be collected in a large (N=1000) intake sample from the adolescent outpatients units of three Finnish university hospitals. Besides the central psychotic-like experiences, psychosocial protective factors of positive mental health, resilience, and social networks will also be simultaneously assessed, as well as potentiating risk factors such as trauma, sleep disorders, affective symptoms, borderline personality traits, and substance use. The predictive value of psychotic-like experiences, in isolation and in interaction with the other measures, will assessed with an inclusive national register follow-up of psychosis diagnoses and all-causes psychiatric hospitalization. The study will thus produce risk algorithms for everyday use in psychiatric care. For immediate applicability of results, tools for computerized self-report and automatic risk calculation will be made available for clinical use.
ANALYSIS PLAN To ensure a strong foundation for the primary predictor of positive psychotic-like experience (PLE) intensity, the structural validity of the YEAH questionnaire will be assessed with a theory-driven confirmatory bifactor model, taking into account the ordinal nature of items. In the case of unsatisfactory fit, exploratory analyses will be performed.
The main pre-planned outcome analysis will be baseline latent positive and negative PLE levels on the YEAH questionaire and their interaction predicting the follow-up transition to psychosis. Secondary analyses using the same predictors will use all-causes hospitalization as the outcome, as an indicator of a general deterioration of mental health. Exploratory LASSO analyses of the same outcomes will include as additional predictors all baseline assessments of psychosocial health and symptoms, as well as the symptom stability in the questionnaire follow-up. Best analysis and reporting practices recommended for the field will be followed (Studerus et al, 2017), to minimize chance findings and to allow accurate replication.
Power analyses The expected minimum sample size of 900 questionnaires is conservative for the planned main analyses. In our previous Helsinki Prodromal Study with a similar sampling strategy (Therman et al., 2014), 3.5% of respondents were diagnosed with psychosis within one year. With the consequently expected group sizes of 31 (psychosis) and 869 (others) and error probabilities α and β conservatively both set at 5%, a sensitivity analysis for a one-tailed t-test indicates a required effect size of 0.60 (Cohen's d) for the outcome-group difference in PLE intensity, which is the worst-case scenario. In our previous study, the d for the total score on the fairly non-specific Prodromal Questionnaire was 0.50, and the effect sizes for the brief questionnaires in the Kline et al. (2015) and Kobayashi et al. (2008) studies all corresponded to a d of 1.1 or greater. A d of 0.90 is a thus a conservative expectation with the new questionnaire, which would require a sample size of only 420. With a cut-off set to 20% test positives, already this effect size would achieve clinical usefulness as an initial screen, when the two-year psychosis rate is 5% (sensitivity 50%, positive predictive value 13%, diagnostic odds ratio 4.4). With a realistically obtainable d of 1.5 as the best-case scenario, the questionnaire screening would under the same conditions be highly useful (sensitivity 71%, positive predictive value 18%, diagnostic odds ratio 12).
DOCUMENTATION AND QUALITY Possibilities for continued use of the data will be ensured by carefully documenting data collection methods, external circumstances, as well as the contents of the dataset. For documentation, the project will use the Data Documentation Initiative (DDI, version 3.2 with lifecycle support) international metadata standard.
The primary database will contain a change log and previous versions will be archived with each revision. Main databases of the full dataset with version numbers and change logs will be maintained at the National Institute for Health and Welfare.
DATA CORRECTNESS The primary questionnaire data will be entered directly by the respondents as multiple-choice items on tablet computers. Aggregated and individual responses will be reviewed by clinical workers immediately afterwards and discussed with the respondents as part of clinical routine. There will therefore not be a separate data entry stage with associated data entry errors.
The secondary coded interview data will be entered by clinical workers directly into the database, and will be reviewed by the treating physician as part of clinical practice. Entry fields will be multiple-choice or limited to allowed values.
Correct identification of data will be ensured by the clinical worker entering as primary identifier the unique Finnish national identification number, with the full name as secondary information. The identification number is subject to immediate automatic checks using the builtin check character and the associated age, and it will later be cross-checked with the name in local register follow-ups.
Imported register data will be screened for disallowed values, and dates cross-checked with the primary study database to ensure correct person identification. Local and nationally aggregated register data coverage will be compared to ensure completeness.
ADDITIONAL SECURITY OF PERSONAL IDENTIFYING INFORMATION Personal identifying information will be stored separately from other electronic data, and linked to clinical data by a new random study identifier (a uuid) generated at THL. A uuid, or universally unique identifier, is a 128 bit number, ISO/IEC 9834-8:2014). All analyses will be conducted using datasets without other identifying information than the study uuid. The file with personally identifying information will additionally be encrypted with a study-specific password known only to participating researchers.
DATA SHARING AND LONG-TERM PRESERVATION All materials will be permanently stored in the THL archives as per the Finnish Archive Law (23.9.1994/831).
To ensure maximum discoverability, metadata including codebooks and employed analysis scripts will be archived at the Finnish Social Science Data Archive (FSD) and within the EUDAT metadata infrastructure B2FIND.
Open sharing of the data is not possible as consent for publication of the raw data is not obtained from the participants and the dataset could pose a threat to the confidentiality of their sensitive information.
Due to the sensitive nature of the data and commitments made to the participants on their consent form, the compiled data itself will be managed solely by the National Institute for Health and Welfare (THL) and will be made available to other parties only by separate agreement and in anonymized, redacted form. This redaction work will be in compliance with national guidelines and additionally follow the most restrictive recommended approach among the following authoritative resources:
- US National Institutes of Health Data Sharing Policy
- UK Data Archive Anonymization/Quantitative
- Standards published in leading medical journals (e.g. BMJ 2010;340:c181, doi: 10.1136/bmj.c181)
- Conditions
- Psychotic Disorders, Psychiatric Hospitalization, Prodromal Symptoms, Cannabis Use, Trauma, Psychological
- Being tested
- Psychiatric questionnaires, Semi-structured psychiatric interview
- Keywords
- adolescent, outpatients, questionnaire, psychotic-like symptoms, psychosis risk
- Medical subject headings
- Psychotic Disorders, Prodromal Symptoms, Psychological Trauma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Psychiatric questionnairesDiagnostic test
Participants will fill in the following questionnaires as part of routine intake assessments:
Generalised Anxiety Disorder Assessment (GAD-7); Mini-Social Phobia Inventory; Beck Depression Inventory 21A; Pittsburgh Sleep Quality Index; Insomnia Severity Index; Youth Experiences and Health Questionnaire; Adolescent Dissociative Experiences Scale (abbr.); Adolescent Peer Relations Instrument (APRI-B + cyberbullying, abbr.); Adolescent Trauma and Dissociation Scale (abbr.); Alcohol Use Disorders Identification Test; Alcohol, Smoking and Substance Involvement Screening Test - Lite (extended); Nicotine Questionnaire incl. Heavy Smoking Index; Internet Addiction Test (abbr.); European School Survey Project on Alcohol and Other Drugs 2015 Social Media Use and Computer Gaming; McMaster Family Assessment Device - General Functioning positive items; Multidimensional Scale of Perceived Social Support; Brief Resilience Scale; The Short Warwick-Edinburgh Mental Well-Being Scale
Semi-structured psychiatric interviewDiagnostic test
Kiddie Schedule for Affective Disorders and Schizophrenia, version K-SADS-PL 2013.
| Study group | Role | What they receive |
|---|---|---|
| Participants | The adolescent psychiatric organizations of the Helsinki University Central Hospital (serving the capital region's 1.1 million inhabitants), the Tampere University Hospital (catchment area of 500.000 inhabitants), and the Oulu University Hospital (catchment area of 500.000 inhabitants) have agreed to implement the data collection as part of routine intake assessments for patients aged 15-17. All consenting patients are enrolled; the only exclusion criterion is a previous diagnosis of psychotic disorder.
The participants fill in psychiatric self-report questionnaires, and their structured diagnostic interview data are collected with their permission. Receives: Diagnostic Test: Psychiatric questionnaires; Diagnostic Test: Semi-structured psychiatric interview |
What is being measured
The primary outcome is the main question the study is designed to answer.
First psychosis disorder diagnosis
National health care register diagnosis of non-organic psychosis
Measured: 5 years from recruitment (baseline questionnaire assessment)
Secondary outcomes (2)
Need for psychiatric care
National health care register outpatient visits
Measured: 5 years from recruitment (baseline questionnaire assessment)
Psychiatric hospitalization
National health care register record of hospitalization
Measured: 5 years from recruitment (baseline questionnaire assessment)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2017
- Study start1 Dec 2019
- Primary completion31 Dec 2024 (estimated)
- Study completion31 Dec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Psychotic DisordersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Finnish Institute for Health and Welfare
- Sponsor type
- Other government
- Collaborators
- Hospital District of Helsinki and Uusimaa, Pirkanmaa Hospital District, Northern Ostrobothnia Hospital District
- Responsible party
- Sponsor
- Investigators
- Sebastian Therman, PhD, Study director, Sebastian.Therman@THL.fiMauri Marttunen, MD, PhD, Principal investigator, Hospital District of Helsinki and Uusimaa
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03332966
- Sponsor's protocol ID
- 684/6.02.01/2016
- Other IDs
- 207/13/03/00/16, HUS/396/2017, R16157, 314/2016
- Acronym
- YEAH
- Status last verified
- Sep 2024
- First submitted
- 1 Nov 2017
- Last updated
- 25 Sep 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Due to the sensitive nature of the data and commitments made to the participants on their consent form, the compiled data itself will be managed solely by the National Institute for Health and Welfare (THL) and will be made available to other parties only by separate agreement and in anonymized, redacted form.
Study at a glance
From the registry record, last updated by the sponsor on 25 Sep 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Youth Experiences and Health (YEAH) Study - Psychological Symptoms and Resources As Predictors of Mental Health Among Treatment-seeking Adolescents
- ClinicalTrials.gov ID
- NCT03332966
- Acronym / sponsor ID
- YEAH / 684/6.02.01/2016
- Conditions
- Psychotic Disorders, Psychiatric Hospitalization, Prodromal Symptoms, Cannabis Use, Trauma, Psychological
- Keywords
- adolescent, outpatients, questionnaire, psychotic-like symptoms, psychosis risk
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Finnish Institute for Health and WelfareOther government
- Collaborators
- Hospital District of Helsinki and Uusimaa, Pirkanmaa Hospital District, Northern Ostrobothnia Hospital District
- Study start
- 1 Dec 2019 (actual)
- Primary completion
- 31 Dec 2024 (estimated)
- Study completion
- 31 Dec 2024 (estimated)
- First posted
- 6 Nov 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to identify unusual experiences and psychiatric symptoms that indicate a heightened risk for severe mental disorders - especially psychoses. It is important to develop reliable questionnaire methods that are cost-effective in first-stage screening, leading to in-depth assessments and targeted care. However, existing psychosis-risk questionnaires are limited in content, intended for adults, and have been insufficiently tested for actual predictive value. Therefore we will collect a new, large dataset from an unselected group of adolescents entering psychiatric care in three major urban areas of Finland. Comprehensive national health care registers will be used to assess how well the selected experiences and symptoms predict the participants' mental health over the following few years.
Detailed description
The current research will identify specific self-reported risk symptoms for psychosis and psychiatric hospitalization. Data will be collected in a large (N=1000) intake sample from the adolescent outpatients units of three Finnish university hospitals. Besides the central psychotic-like experiences, psychosocial protective factors of positive mental health, resilience, and social networks will also be simultaneously assessed, as well as potentiating risk factors such as trauma, sleep disorders, affective symptoms, borderline personality traits, and substance use. The predictive value of psychotic-like experiences, in isolation and in interaction with the other measures, will assessed with an inclusive national register follow-up of psychosis diagnoses and all-causes psychiatric hospitalization. The study will thus produce risk algorithms for everyday use in psychiatric care. For immediate applicability of results, tools for computerized self-report and automatic risk calculation will be made available for clinical use.
ANALYSIS PLAN To ensure a strong foundation for the primary predictor of positive psychotic-like experience (PLE) intensity, the structural validity of the YEAH questionnaire will be assessed with a theory-driven confirmatory bifactor model, taking into account the ordinal nature of items. In the case of unsatisfactory fit, exploratory analyses will be performed.
The main pre-planned outcome analysis will be baseline latent positive and negative PLE levels on the YEAH questionaire and their interaction predicting the follow-up transition to psychosis. Secondary analyses using the same predictors will use all-causes hospitalization as the outcome, as an indicator of a general deterioration of mental health. Exploratory LASSO analyses of the same outcomes will include as additional predictors all baseline assessments of psychosocial health and symptoms, as well as the symptom stability in the questionnaire follow-up. Best analysis and reporting practices recommended for the field will be followed (Studerus et al, 2017), to minimize chance findings and to allow accurate replication.
Power analyses The expected minimum sample size of 900 questionnaires is conservative for the planned main analyses. In our previous Helsinki Prodromal Study with a similar sampling strategy (Therman et al., 2014), 3.5% of respondents were diagnosed with psychosis within one year. With the consequently expected group sizes of 31 (psychosis) and 869 (others) and error probabilities α and β conservatively both set at 5%, a sensitivity analysis for a one-tailed t-test indicates a required effect size of 0.60 (Cohen's d) for the outcome-group difference in PLE intensity, which is the worst-case scenario. In our previous study, the d for the total score on the fairly non-specific Prodromal Questionnaire was 0.50, and the effect sizes for the brief questionnaires in the Kline et al. (2015) and Kobayashi et al. (2008) studies all corresponded to a d of 1.1 or greater. A d of 0.90 is a thus a conservative expectation with the new questionnaire, which would require a sample size of only 420. With a cut-off set to 20% test positives, already this effect size would achieve clinical usefulness as an initial screen, when the two-year psychosis rate is 5% (sensitivity 50%, positive predictive value 13%, diagnostic odds ratio 4.4). With a realistically obtainable d of 1.5 as the best-case scenario, the questionnaire screening would under the same conditions be highly useful (sensitivity 71%, positive predictive value 18%, diagnostic odds ratio 12).
DOCUMENTATION AND QUALITY Possibilities for continued use of the data will be ensured by carefully documenting data collection methods, external circumstances, as well as the contents of the dataset. For documentation, the project will use the Data Documentation Initiative (DDI, version 3.2 with lifecycle support) international metadata standard.
The primary database will contain a change log and previous versions will be archived with each revision. Main databases of the full dataset with version numbers and change logs will be maintained at the National Institute for Health and Welfare.
DATA CORRECTNESS The primary questionnaire data will be entered directly by the respondents as multiple-choice items on tablet computers. Aggregated and individual responses will be reviewed by clinical workers immediately afterwards and discussed with the respondents as part of clinical routine. There will therefore not be a separate data entry stage with associated data entry errors.
The secondary coded interview data will be entered by clinical workers directly into the database, and will be reviewed by the treating physician as part of clinical practice. Entry fields will be multiple-choice or limited to allowed values.
Correct identification of data will be ensured by the clinical worker entering as primary identifier the unique Finnish national identification number, with the full name as secondary information. The identification number is subject to immediate automatic checks using the builtin check character and the associated age, and it will later be cross-checked with the name in local register follow-ups.
Imported register data will be screened for disallowed values, and dates cross-checked with the primary study database to ensure correct person identification. Local and nationally aggregated register data coverage will be compared to ensure completeness.
ADDITIONAL SECURITY OF PERSONAL IDENTIFYING INFORMATION Personal identifying information will be stored separately from other electronic data, and linked to clinical data by a new random study identifier (a uuid) generated at THL. A uuid, or universally unique identifier, is a 128 bit number, ISO/IEC 9834-8:2014). All analyses will be conducted using datasets without other identifying information than the study uuid. The file with personally identifying information will additionally be encrypted with a study-specific password known only to participating researchers.
DATA SHARING AND LONG-TERM PRESERVATION All materials will be permanently stored in the THL archives as per the Finnish Archive Law (23.9.1994/831).
To ensure maximum discoverability, metadata including codebooks and employed analysis scripts will be archived at the Finnish Social Science Data Archive (FSD) and within the EUDAT metadata infrastructure B2FIND.
Open sharing of the data is not possible as consent for publication of the raw data is not obtained from the participants and the dataset could pose a threat to the confidentiality of their sensitive information.
Due to the sensitive nature of the data and commitments made to the participants on their consent form, the compiled data itself will be managed solely by the National Institute for Health and Welfare (THL) and will be made available to other parties only by separate agreement and in anonymized, redacted form. This redaction work will be in compliance with national guidelines and additionally follow the most restrictive recommended approach among the following authoritative resources:
- US National Institutes of Health Data Sharing Policy
- UK Data Archive Anonymization/Quantitative
- Standards published in leading medical journals (e.g. BMJ 2010;340:c181, doi: 10.1136/bmj.c181)
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 5 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Participants | – | Diagnostic Test: Psychiatric questionnaires, Diagnostic Test: Semi-structured psychiatric interviewThe adolescent psychiatric organizations of the Helsinki University Central Hospital (serving the capital region's 1.1 million inhabitants), the Tampere University Hospital (catchment area of 500.000 inhabitants), and the Oulu University Hospital (catchment area of 500.000 inhabitants) have agreed to implement the data collection as part of routine intake assessments for patients aged 15-17. All consenting patients are enrolled; the only exclusion criterion is a previous diagnosis of psychotic disorder. The participants fill in psychiatric self-report questionnaires, and their structured diagnostic interview data are collected with their permission. |
Who may qualify
- Ages
- 15 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- All patients in the adolescent health clinics in three hospital districts of Finland.
Key inclusion criteria (1 listed)
- Start of care in adolescent mental health clinic
Key exclusion criteria (1 listed)
- Previous diagnosis of psychotic disorder
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Psychiatric questionnairesParticipants will fill in the following questionnaires as part of routine intake assessments: Generalised Anxiety Disorder Assessment (GAD-7); Mini-Social Phobia Inventory; Beck Depression Inventory 21A; Pittsburgh Sleep Quality Index; Insomnia Severity Index; Youth Experiences and Health Questionnaire; Adolescent Dissociative Experiences Scale (abbr.); Adolescent Peer Relations Instrument (APRI-B + cyberbullying, abbr.); Adolescent Trauma and Dissociation Scale (abbr.); Alcohol Use Disorders Identification Test; Alcohol, Smoking and Substance Involvement Screening Test - Lite (extended); Nicotine Questionnaire incl. Heavy Smoking Index; Internet Addiction Test (abbr.); European School Survey Project on Alcohol and Other Drugs 2015 Social Media Use and Computer Gaming; McMaster Family Assessment Device - General Functioning positive items; Multidimensional Scale of Perceived Social Support; Brief Resilience Scale; The Short Warwick-Edinburgh Mental Well-Being Scale | Diagnostic test | Participants |
| Semi-structured psychiatric interviewKiddie Schedule for Affective Disorders and Schizophrenia, version K-SADS-PL 2013. | Diagnostic test | Participants |
Primary outcome
First psychosis disorder diagnosis
Time frame: 5 years from recruitment (baseline questionnaire assessment)
National health care register diagnosis of non-organic psychosis
2 secondary outcomes
Need for psychiatric care
Time frame: 5 years from recruitment (baseline questionnaire assessment)
Psychiatric hospitalization
Time frame: 5 years from recruitment (baseline questionnaire assessment)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2024.
- Home page of the study (in Finnish)Link provided by the sponsor.
- Finnish Institute for Health and Welfare institutional study catalog entry (in Finnish)Link provided by the sponsor.
- Individual participant dataSharing planned: Undecided. Due to the sensitive nature of the data and commitments made to the participants on their consent form, the compiled data itself will be managed solely by the National Institute for Health and Welfare (THL) and will be made available to other parties only by separate agreement and in anonymized, redacted form.
Related trials for Psychotic Disorders
RecruitingPhase 2
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
Schizophrenia
RecruitingPhase 3
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
Schizophrenia
Recruiting
Magnetic Seizure Therapy for Schizophrenia - Trial
Treatment Resistant Schizophrenia, Schizophrenia
RecruitingObservational study
Sensory Profile and Early Clinical Signs of Calm Room Users
Psychotic Disorders, Personality Disorders
Not yet recruitingObservational study
Validation of Wearable Core Body Temperature-Based Circadian Rhythm Digital Biomarkers
Mood Disorders, Major Depressive Diorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sebastian Therman, PhD study director
Sebastian.Therman@THL.fi
Mauri Marttunen, MD, PhD principal investigator
Hospital District of Helsinki and Uusimaa
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Psychotic Disorders and Psychiatric Hospitalization, run by Finnish Institute for Health and Welfare at 3 sites in Finland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 25 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Finland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Sebastian Therman, PhD (+358445405559, Sebastian.Therman@THL.fi), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
First psychosis disorder diagnosis (time frame: 5 years from recruitment (baseline questionnaire assessment)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2024.